Copyright
©The Author(s) 2017.
World J Hepatol. Dec 28, 2017; 9(36): 1340-1345
Published online Dec 28, 2017. doi: 10.4254/wjh.v9.i36.1340
Published online Dec 28, 2017. doi: 10.4254/wjh.v9.i36.1340
Table 1 Baseline characteristics
| Characteristics | Total (n = 246) | < 75 yr (n = 167) | ≥ 75 yr (n = 79) | P value |
| Sex (male) | 103 (42) | 65 (39) | 37 (47) | 0.239 |
| Age (yr) | 69 (29-88) | 65 (29-74) | 78 (75-88) | < 0.001 |
| Body weight (kg) | 53 (35-91) | 53 (38-91) | 53 (35-78) | 0.527 |
| Cirrhosis | 51 (21) | 30 (18) | 21 (26) | 0.120 |
| HCV RNA (log10IU/mL) | 6.1 (1.6-7.3) | 6.1 (1.6-7.3) | 6.1 (4.0-6.8) | 0.337 |
| Hemoglobin (g/dL) | 13.6 (9.0-16.8) | 13.6 (9.5-16.8) | 13.3 (9.0-15.9) | 0.163 |
| Platelets (× 109/L) | 156 (26-340) | 167 (26-340) | 132 (57-278) | 0.001 |
| Aspartate aminotransaminase (U/L) | 42 (17-191) | 40 (17-191) | 45 (20-155) | 0.140 |
| Alanine aminotransaminase (U/L) | 38 (11-319) | 38 (12-319) | 37 (11-167) | 0.341 |
| eGFR (mL/min per 1.73 m2) | 72 (36-132) | 76 (38-132) | 63 (36-98) | < 0.001 |
| α-fetoprotein (ng/mL) | 4 (1-382) | 4 (1-382) | 4 (1-74) | 0.525 |
| Fib-4 index | 3.3 (0.5-23.2) | 2.5 (0.5-23.2) | 4.4 (1.5-10.7) | < 0.001 |
| NS5A RAVs | ||||
| Y93 | 22 (29) | 10 (21) | 12 (43) | 0.146 |
| L31 | 6 (8) | 3 (6) | 3 (11) | 0.798 |
| Y93/L31 | 5 (7) | 4 (9) | 1 (4) | 0.645 |
| Treatment experienced | 52 (21) | 41 (25) | 11 (14) | 0.064 |
| Previous HCC treatment | 16 (7) | 11 (7) | 5 (6) | 0.841 |
- Citation: Ozono Y, Nagata K, Hasuike S, Iwakiri H, Nakamura K, Tsuchimochi M, Yamada Y, Takaishi Y, Sueta M, Miike T, Tahara Y, Yamamoto S, Shide K, Hidaka T, Kubuki Y, Kusumoto K, Ochiai T, Kato J, Komada N, Hirono S, Kuroki K, Shigehira M, Shimoda K. Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1. World J Hepatol 2017; 9(36): 1340-1345
- URL: https://www.wjgnet.com/1948-5182/full/v9/i36/1340.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i36.1340